Abstract
Abstract Research concerning “cancer energetics” has become a popular area of investigation. This topic comprises two distinct fields: energetics at (1) the cellular level and (2) the whole organism level. Both of these have relevance to Cancer Risk and Cancer Prevention.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kim J W, Dang CV (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66:8927–8930
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566
Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671–686
Heuson JC, Legros N (1972) Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 32:226–232
Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M (2007) Association of diet-induced hyperin-sulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99:1793–1800
Pollak, M. Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. Abstr No 524, Proceedings of 2006 ASCO Annual Meeting
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51
Ma J, Haojie L, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano J, Pollak M, Stampfer M, Predia gnostic Body Mass Index, plasma c- peptide concertration, and prostate-cancer-specific mortality in men with prostate cancer. Lancet Oncology in press, 2008
Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642–1646
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804–10812
Phoenix KN, Vumbaca F, Claffey KP (2008) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat Feb 7; advance on-line publication
Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB (2007) Systemic treatment with the antidia-betic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745–6752
Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko AV (2005) Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 139:721–723
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258
Kelishadi R, Cook SR, Motlagh ME, Gouya MM, Ardalan G, Motaghian M, Majdzadeh R, Ramezani MA (2008) Metabolically obese normal weight and phenotypically obese metabolically normal youths: the CASPIAN study. J Am Diet Assoc 108:82–90
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Pollak, M. (2009). Energy Metabolism, Cancer Risk, and Cancer Prevention. In: Senn, HJ., Kapp, U., Otto, F. (eds) Cancer Prevention II. Recent Results in Cancer Research, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69297-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-69297-3_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69296-6
Online ISBN: 978-3-540-69297-3
eBook Packages: MedicineMedicine (R0)